Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Back to School Savings: Save up to 30% on print books and eBooks. No promo code needed.
Back to School Savings: Save up to 30%
Motor Neurone Disease
1st Edition - April 1, 2024
Editors: Pamela J. Shaw, Janine Kirby
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 4 1 1 6 - 4
International Review in Neurobiology serial highlights new advances in the field with this new volume presenting interesting chapters. Each chapter is written by an international… Read more
Purchase Options
International Review in Neurobiology serial highlights new advances in the field with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in International Review on Neurobiology serials
- Updated release includes the latest information on Motor Neuron Disease
Undergraduates, graduates, academics, and researchers in the field of motor neuron disease
1. Clinical features, differential diagnosis and pathology
Michael van Es
2. Recent advances in genetics of familial and sporadic ALS
Ammar Al Chalabi
3. Non-coding genome contribution to ALS
John Cooper-Knock
4. Contribution of neurophysiology to the diagnosis and monitoring ALS
James Alix
5. Advances in symptom management and monitoring disease progression
Chris McDermott
6. Use of biomarkers in clinical trials and future developments that will help identify new biomarkers
Andrea Malaspina
7. Application of systems biology to identify therapeutic targets
Janine Kirby and Bryan Traynor
8. Evidence of mitochondrial dysfunction (in ALS) and how to measure it in model systems
Heather Mortiboys and Kurt de Vos
9. Current neuroprotective therapies and future prospects
Pamela Shaw
10. The role of glial cells in ALS
Rickie Patani
11. Dysregulation of RNA biology in ALS
Guillaume Hautbergue
12. New developments in pre-clinical models of ALS to guide translation
Ludo van den Bosch
- No. of pages: 322
- Language: English
- Published: April 1, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443141164
PS
Pamela J. Shaw
Professor Dame Pam Shaw is Professor of Neurology at the University of Sheffield and Director of: the Sheffield Institute for Translational Neuroscience (SITraN); the NIHR Sheffield Biomedical Research Centre for Translational Neuroscience; the Sheffield Care and Research Centre for Motor Neuron Disorders and the cross-faculty Sheffield Neuroscience Institute.
She is a Clinician Scientist in Neurology, formerly a Wellcome Trust Senior Fellow and an NIHR Senior Investigator. Her team investigates genetic, molecular and neurochemical mechanisms underlying ALS/MND; investigates new therapeutic targets and translates new neuroprotective and symptomatic treatment approaches into the clinic, including genetic therapy approaches. She has active programmes in systematic biosample collection and biomarker identification in ALS/MND.
She has authored more than 550 publications (H-index 116). Her research is funded by NIHR, the MRC, Wellcome Trust, MND Association, MyName’5 Doddie Foundation, EU and biotech/pharmaceutical industry partners.
From 2009-2016 she initiated and led the national UK Clinical Studies Group for ALS/MND, a clinical research and trials network which links 20 ALS/MND Care and Research Centres. Prof. Shaw has taken part in more than 25 ALS/MND clinical trials, including roles as Chief Investigator and Steering Committee member and also including several academic-led studies. She is an active member of the European Network for the Cure of ALS (ENCALS) and the TRICALS clinical trials platform.
Affiliations and expertise
Professor of Neurology, Academic Neurology Unit, Division of Genomic Medicine, University of Sheffield, Sheffield, UKJK
Janine Kirby
My research interests encompass the genetics of neurodegenerative diseases and how gene expression profiling can be used to investigate the pathogenic mechanisms of neurodegeneration and to identify diagnostic and prognostic biomarkers. I have used both Sanger and next generation sequencing (exome and targeted) to screen known and establish novel causative genes in ALS and other neurodegenerative diseases (NDD). Most recently, I demonstrated the value of genetic screening in all patients with ALS, identifying actionable clinical results in patients who would normally not be offered it. I have performed genotype/phenotype correlations to link genetic, clinical, and neuropathological findings with multiple ALS genes including SOD1, TARDBP, FUS, C9ORF72, ANG, OPTN and most recently TBK1.
Sampling of CNS and peripheral tissues, as well as animal and cellular models, has been used to establish pathogenic mechanisms involved in both genetic and sporadic ALS. One of these studies established the dysregulation of NRF2, an important cell survival transcription factor, and this is now a therapeutic target for ALS. Expression profiling of CNS, blood, and fibroblast samples from genetic variants of MND and sporadic cases has also identified distinct gene signatures associated with the different genetic subtypes. Variation in miRNAs and other non-coding RNAs are also emerging as potential disease biomarkers. MiRNA profiling in serum and CSF by quantitative PCR, microarrays and small RNA sequencing has determined multiple miRNAs dysregulated in ALS. Finally, gene expression profiling of longitudinal blood samples from patient’s blood samples have established the effect of low-dose interleukin-2 and demonstrated the effect of the drug on the blood transcriptome as well as the patient’s personalized response, demonstrating the importance of a personalized medicine approach for the future.
Affiliations and expertise
Professor in Neurogenetics
Department of Neuroscience
University of Sheffield